225 related articles for article (PubMed ID: 37528405)
1. Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry : Trends in antithrombotic therapy use in China.
Liu X; Feng G; Marler SV; Huisman MV; Lip GYH; Ma C
Thromb J; 2023 Aug; 21(1):83. PubMed ID: 37528405
[TBL] [Abstract][Full Text] [Related]
2. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
[TBL] [Abstract][Full Text] [Related]
5. Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.
Beier L; Lu S; França LR; Marler S; Lip GYH; Huisman MV; Teutsch C; Halperin JL; Zint K; Diener HC; Baker L; Ma CS; Paquette M; Bartels DB; Dubner SJ; Lyrer P; Senges J; Rothman KJ
PLoS One; 2022; 17(10):e0274237. PubMed ID: 36201473
[TBL] [Abstract][Full Text] [Related]
6. Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry.
Ma C; Riou França L; Lu S; Diener HC; Dubner SJ; Halperin JL; Li Q; Paquette M; Teutsch C; Huisman MV; Lip GYH; Rothman KJ;
J Arrhythm; 2020 Jun; 36(3):408-416. PubMed ID: 32528565
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme.
Mazurek M; Halperin JL; Huisman MV; Diener HC; Dubner SJ; Ma CS; Rothman KJ; Healey JS; Teutsch C; Paquette M; França LR; Lu S; Bartels DB; Lip GYH
Europace; 2020 Jan; 22(1):47-57. PubMed ID: 31651951
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
Huisman MV; Teutsch C; Lu S; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Lohmann R; Gurusamy VK; Bartels DB; Lip GYH;
Clin Res Cardiol; 2022 May; 111(5):548-559. PubMed ID: 35294623
[TBL] [Abstract][Full Text] [Related]
9. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Huisman MV; Lip GY; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Teutsch C; Zint K; Ackermann D; Clemens A; Bartels DB
Am Heart J; 2014 Mar; 167(3):329-34. PubMed ID: 24576516
[TBL] [Abstract][Full Text] [Related]
10. Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.
Kozieł M; Teutsch C; Bayer V; Lu S; Gurusamy VK; Halperin JL; Rothman KJ; Diener HC; Ma CS; Huisman MV; Lip GYH;
J Arrhythm; 2021 Aug; 37(4):990-1006. PubMed ID: 34386125
[TBL] [Abstract][Full Text] [Related]
11. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.
McIntyre WF; Conen D; Olshansky B; Halperin JL; Hayek E; Huisman MV; Lip GYH; Lu S; Healey JS
Clin Cardiol; 2018 Jun; 41(6):744-751. PubMed ID: 29546729
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant selection in relation to the SAMe-TT
Ntaios G; Huisman MV; Diener HC; Halperin JL; Teutsch C; Marler S; Gurusamy VK; Thompson M; Lip GYH; Olshansky B;
Hellenic J Cardiol; 2021; 62(2):152-157. PubMed ID: 33338644
[TBL] [Abstract][Full Text] [Related]
13. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.
Apenteng PN; Gao H; Hobbs FR; Fitzmaurice DA;
BMJ Open; 2018 Jan; 8(1):e018905. PubMed ID: 29331969
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program.
Azar RR; Ragy HI; Kozan O; El Khuri M; Bazergani N; Marler S; Teutsch C; Ibrahim M; Lip GYH; Huisman MV
Int J Cardiol Heart Vasc; 2021 Jun; 34():100763. PubMed ID: 33912651
[TBL] [Abstract][Full Text] [Related]
15. Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.
Mazurek M; Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Lip GYH;
Thromb Haemost; 2017 Dec; 117(12):2376-2388. PubMed ID: 29212125
[TBL] [Abstract][Full Text] [Related]
16. Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program.
Mazurek M; Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Zint K; França LR; Lu S; Lip GYH;
Am J Med; 2018 Aug; 131(8):945-955.e3. PubMed ID: 29654720
[TBL] [Abstract][Full Text] [Related]
17. Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF.
Kozieł M; Teutsch C; Halperin JL; Rothman KJ; Diener HC; Ma CS; Marler S; Lu S; Gurusamy VK; Huisman MV; Lip GYH;
PLoS One; 2021; 16(4):e0249524. PubMed ID: 33852611
[TBL] [Abstract][Full Text] [Related]
18. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Bartels DB; Lip GYH;
Am Heart J; 2018 Apr; 198():55-63. PubMed ID: 29653649
[TBL] [Abstract][Full Text] [Related]
19. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry.
Bergler-Klein J; Gotcheva N; Kalējs O; Kalarus Z; Kovačić D; Peršić V; Shlyakhto E; Uuetoa T; Huisman MV; Lip GYH; Vinereanu D;
Am J Ther; 2024 Jan-Feb 01; 31(1):e1-e12. PubMed ID: 38231576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
